CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, presented data from its experimental infection study at the 2007 Pediatric Academic Societies’ (PAS) Annual Meeting being held in Toronto. This study represents an important component of the company’s clinical development program for ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. Results demonstrated the establishment of a safe and reliable RSV infection in the upper respiratory tract of adult volunteers and as a result of this achievement, the company expects to begin a Phase II study evaluating the safety and efficacy of ALN-RSV01 in experimentally infected adults in the second quarter of this year.
